Best Useful Articles

Two Deaths In One Week: It's Not Good To Play Sports With A Big Heart

The tragic news of Chicago Bears defensive end Gaines Adams, 26, and Southern Indiana center Jeron Lewis, 21, whose sudden deaths are both suspected to be from Hypertrophic Cardiomyopathy (HCM), are vital reminders that this deadly disease often goes undetected. Hypertrophic Cardiomyopathy (HCM), a genetic disease which results in a thickening of the heart muscle, is the leading cause of sudden death in children and young adults. It accounts for 40 percent of all deaths on athletic playing fields across the country. Marcia Kelley-Clark, chief deputy coroner for Greenwood County, S.C., said Gaines Adams' relatives were not aware of any kind of medical condition.

Study Shows GHRH-Agonists Can Activate Cardiac Repair After Myocardial Infarction

Despite major therapeutic advances, congestive heart failure remains a leading cause of death and disability. There is currently no therapy that fully reverses heart failure and/or left ventricular (LV) dysfunction, leaving physicians with a great need for viable treatments. A team of physician-scientists from the University of Miami Miller School of Medicine, including a Nobel Laureate, have demonstrated that growth hormone-releasing hormone agonists (GHRH-A) can stimulate major recovery of the heart injured by a heart attack. GHRH is a master regulator of growth hormone that is produced by the brain. Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine in the Cardiovascular Division, was the principal investigator of the study that included fifteen researchers, among them co-senior author Andrew V.

AMA Welcomes New Body To Combat Rheumatic Heart Disease, Australia

AMA Vice President and Chair of the AMA Taskforce on Indigenous Health, Dr Steve Hambleton, said today that RHDAustralia is an important first step towards eradicating rheumatic heart disease among Indigenous people. The Government has provided RHDAustralia with $2.5 million over four years to combat rheumatic heart disease, which is a major killer of Aboriginal and Torres Strait Islander people. "For several years, the AMA has been calling for a coordinated national effort to eradicate rheumatic heart disease among Indigenous people, " Dr Hambleton said. "Acute rheumatic fever and rheumatic heart disease can be prevented if the right screening, management and notification processes - and follow up - are put in place.

BG Medicine Announces Receipt Of CE Mark For Its Galectin-3 Blood Test

BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure. "This is an important point in our development of galectin-3 testing and a milestone for the company, " noted Pieter Muntendam, MD, President and CEO of BG Medicine. "Heart failure is a complex and heterogeneous condition, and the objective of our BGM Galectin-3™

SNM Applauds US Department Of Energy's Move To Develop Domestic Radioisotope Supply

SNM applauds a move by the U.S. Department of Energy's National Nuclear Security Administration (NNSA) to help fund the development of a domestic supply of radioisotopes, which are used to help millions of patients each year through the diagnosis and staging of cancer, thyroid and heart disease. Earlier this week, GE-Hitachi announced their selection by the NNSA to help develop a U.S. supply of Molybdenum-99 (Mo-99). Babcock & Wilcox (B&W) Technical Services Group also announced this week that it has been awarded approximately $9 million from the NNSA for the company's medical isotope production program. The company previously announced a partnership with Covidien to develop medical isotope production.

Piedmont Hospital Installs First Toshiba Vascular X-Ray System With 12 X 12 Mid-Sized Flat Panel Detector

Increasing its ability to provide patients with the highest quality of care, Piedmont Hospital in Atlanta has installed the country's first InfinixTM VF-i vascular X-ray system with the 12" x 12" mid-sized flat panel detector (FPD) from Toshiba America Medical Systems, Inc. The new mid-sized FPD system is equipped with Toshiba's Next Generation Advanced Image Processing (AIP) capabilities and marks the fourth Toshiba Infinix-i system installed by Piedmont Hospital. "Toshiba's Infinix VF-i with the 12" x 12" flat panel detector provides better perspective during electrophysiologic procedures than most traditional flat panel detectors, " said Piedmont Heart Institute physician Harry A.

Cardiovascular Systems Receives Conditional IDE Approval For ORBIT II Coronary Clinical Trial

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites. Dr. Jeffrey Chambers, an interventional cardiologist with Metropolitan Cardiovascular Consultants, Minneapolis, is the principal investigator for ORBIT II. The Diamondback 360° is a minimally invasive catheter, which received FDA 510(k) marketing clearance in 2007 for the treatment of peripheral arterial disease.

St. Jude Medical Showcases Latest Products At Boston Atrial Fibrillation Symposium 2010

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display and demonstrate products and technologies from the company's arrhythmia management portfolio at the 15th annual Boston Atrial Fibrillation (BAF) Symposium. The featured products reflect the company's continued commitment to the treatment of abnormal heart rhythms, including Atrial Fibrillation (AF). St. Jude Medical will feature products and technologies that aid physicians in the diagnosis and treatment of cardiac arrhythmias and cardiovascular disease in the U.S. and around the globe. Physicians can also get hands-on experience with several of the company's latest products by visiting the stations at the company's booths.

MAQUET Cardiovascular Announces Long-Term Follow-Up Data From Landmark 'SMART' Study Reinforce Positive Results For Patients Undergoing OPCAB

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced that long-term results from the landmark SMART (Surgical Management of Arterial Revascularization) study will be presented tomorrow to attendees of the Society of Thoracic Surgeons's 46th Annual Meeting by John Puskas, M.D., Chief of Cardiac Surgery, Emory Crawford Long Hospital, Associate Chief of Cardiothoracic Surgery, Emory University, and SMART Study lead investigator. The data provide confirmation of the efficacy of performing Coronary Artery Bypass Graft surgery (CABG) while the patient's heart continues to beat a procedure known as Off-Pump Coronary Artery Bypass (OPCAB).

Medtronic Receives FDA Approval For First Replacement Heart Valve Implanted Without Surgery

In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody® Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first transcatheter heart valve to receive FDA approval. Delivered through a catheter requiring only a small incision, the Melody valve will benefit children and adults who are born with a malformation of their pulmonary valve, which is the valve between the heart and lungs. These patients often require open-heart surgery to restore effective blood flow to their lungs.

Best Useful Articles © Dimitrov Dmitriy
Designer Dimitrov Dmytriy